FDA Lacked Risk, Supply Recovery Plan in Infant Formula Shortage

The FDA fell short in its risk management plans and supply recovery when it responded to the 2022 infant formula shortage, according to a new report from national science and medicine advisers.

The National Academies of Sciences, Engineering, and Medicine in a report released Thursday found various weaknesses the Food and Drug Administration faced when it took action on the 2022 infant formula shortage.

Several consumer complaints in late 2021 and early 2022 alleged safety concerns at Abbott Laboratories’ Sturgis, Mich., production facility, which prompted the FDA to conduct an inspection. Abbott voluntarily ceased production at the facility and ...